POSB211 Is an Early Access Program for an Oncology Drug an Asset in the French Pricing and Reimbursement Pathway?
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.705
https://www.valueinhealthjournal.com/article/S1098-3015(21)02500-6/fulltext
Title :
POSB211 Is an Early Access Program for an Oncology Drug an Asset in the French Pricing and Reimbursement Pathway?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02500-6&doi=10.1016/j.jval.2021.11.705
First page :
Section Title :
Open access? :
No
Section Order :
10235